101363-10-4 Usage
Pharmaceutical Applications
A tricyclic fluoroquinolone formulated as the hydrochloride salt. It is inactive against Gram-positive cocci with MICs >2 mg/L. It displays weak activity in vitro against Enterobacteriaceae with the MIC for most species >1 mg/L. Activity against Ps. aeruginosa is poor (MIC 16–32 mg/L). After loading doses of 400 and 600 mg followed with 9 days of either 200 or 300 mg, mean peak plasma levels were around 4.5–7 mg/L, respectively. The mean apparent elimination halflife was 44 h. Approximately 50% is eliminated in the urine.It has been used in urinary tract infection and chronic prostatitis, but clinical experience is limited.
Check Digit Verification of cas no
The CAS Registry Mumber 101363-10-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,0,1,3,6 and 3 respectively; the second part has 2 digits, 1 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 101363-10:
(8*1)+(7*0)+(6*1)+(5*3)+(4*6)+(3*3)+(2*1)+(1*0)=64
64 % 10 = 4
So 101363-10-4 is a valid CAS Registry Number.
InChI:InChI=1/C17H18FN3O3S.ClH/c1-19-2-4-20(5-3-19)14-12(18)8-10-13-16(14)25-7-6-21(13)9-11(15(10)22)17(23)24;/h8-9H,2-7H2,1H3,(H,23,24);1H
101363-10-4Relevant articles and documents
Quinolonecarboxylic Acids. 2. Synthesis and Antibacterial Evaluation of 7-Oxo-2,3-dihydro-7H-pyridobenzothiazine-6-carboxylic Acids
Cecchetti, Violetta,Fravolini, Arnaldo,Fringuelli, Renata,Mascellani, Giuseppe,Pagella, Piergiuseppe,et al.
, p. 465 - 473 (2007/10/02)
A series of pyridobenzothiazine acid derivatives was synthesized and their in vitro antibacterial activity was evaluated.The 1,4-benzothiazine intermediates, which by Gould-Jacobs quinoline synthesis produced pyridobenzothiazine acids, were prepared by hydrolytic basic cleavage of substituted 2-aminobenzothiazoles and successive cyclocondensation with 1-bromo-2-chloroethane or alternatively with monochloroacetic acid, hence reduction by LiAlH4.The pyridobenzothiazine acids 10c, 30, and 31 show potent antibacterial activities against Gram-positive and Gram-negative pathogens.Structure-activity relationships are discussed.The compound 9-fluoro-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyridobenzothiazine-6-carboxylic acid (31) (MF-934) has been found to possess, together with the antibacterial activity, a weak acute toxicity and interesting pharmacokinetic characteristics in several animal species (rat, dog, monkey, man).
